Enhancement of Solubility of Artemisinin and Curcumin by Co-Solvency Approach for Application in Parenteral Drug Delivery System

Vaishali Tejas Thakkar, Rachana Dhankecha, Mukesh Gohel, Purvi Shah, Tosha Pandya, Tejal Gandhi

DOI: http://dx.doi.org/10.5138/09750215.1868


The aim of present study was to enhance solubility of poorly soluble antimalarial drugs, Artemisinin and Curcumin by adopting  Co-solvency approach and to develop parenteral aqueous injectable solution. Solubility enhancement of both drugs was achieved using co-solvency approach. The parenteral injection was prepared by using a ternary co-solvent system which comprised of benzyl alcohol, PEG 400 and tween 80 (as surfactant). Solubility of Artemisinin and Curcumin was found to be higher in benzyl alcohol and PEG 400. Co-solvent system comprising of  benzyl alcohol, PEG 400 and tween 80 in volume fraction of 0.3, 0.9 and 0.2 respectively showed the minimum required solubility of Artemisinin (90 mg per ml) and Curcumin (180 mg per ml). The parenteral injectable formulation was characterized for pH, clarity, viscosity, osmolarity and sterility and the stated parameters were found in acceptable range.  In-vitro erythrocyte toxicity study showed that intravenous administration of optimized formulation will be safe. In-vitro antimalarial assay indicated that efficacy of artemisinin and curcumin parenteral formulation was greater than quinine and combination of Artemether and Lumefantrine. Stability study of the optimized batch showed no change in physical and chemical characteristics. Based on study, one can conclude that Artemisinin and Curcumin can be successfully formulated as parenteral injectable formulation by co-solvency approach for the effective treatment of malarial infection


Solubility, Co-solvency, Artemisinin, Curcumin, Parenteral injection, In-vitro evaluation

Full Text:



Okell LC, Drakeley CJ, Bousema T, Whitty CJ, Ghani AC. Modelling the impact of artemisinin combination therapy and long-acting treatments on malaria transmission intensity. PLoS Med. 2008;5:e226. [2] Wykes MN, Horne-Debets J. Dendritic cells: the Trojan horse of malaria? Int J Parasitol. 2012;42:583-7. [3] Cogswell FB. The hypnozoite and relapse in primate malaria. Clin. Microbiol. Rev. 1992;5:26-35. [4] Lee SJ, Seo E, Cho Y. Proposal for a new therapy for drug-resistant malaria using Plasmodium synthetic lethality inference. Int J Parasitol Drugs Drug Resist. 2013;3:119-28. [5] Nosten F, Brasseur P. Combination therapy for malaria. Drugs 2002;62:1315-29. [6] Dende C, Meena J, Nagarajan P, Panda AK, Rangarajan PN, Padmanaban G. Simultaneously targeting inflammatory response and parasite sequestration in brain to treat Experimental Cerebral Malaria. Sci Rep. 2015;5:12671. [7] Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 2003;23:363-98. [8] Padmanaban G, Nagaraj VA, Rangarajan PN. Artemisinin-based combination with curcumin adds a new dimension to malaria therapy. Curr Sci. 2012;102:704-11. [9] Lapenna S, Bilia AR, Morris GA, Nilsson M. Novel artemisinin and curcumin micellar formulations: drug solubility studies by NMR spectroscopy. J. Pharm. Sci. 2009;98:3666-75. [10] Nayak AK, Panigrahi PP. Solubility enhancement of etoricoxib by cosolvency approach. ISRN Physical Chemistry 2012;2012. [11] Strickley RG. Solubilizing excipients in oral and injectable formulations. Pharmaceut Res. 2004;21:201-30. [12] Dezani AB, Pereira TM, Caffaro AM, Reis JM, Serra CHdR. Equilibrium solubility versus intrinsic dissolution: characterization of lamivudine, stavudine and zidovudine for BCS classification. Braz. J. Pharm. Sci. 2013;49:853-63. [13] Roy BC, Kabir M, Rahman M. Ternary phase equilibrium data for acetic acid-water-solvent systems and separation of acetic acid from aqueous solution. J Appl Sci. 2005;5:720-3. [14] Yeh M-K, Chang L-C, Chiou AH-J. Improving tenoxicam solubility and bioavailability by cosolvent system. AAPS PharmSciTech. 2009;10:166-71. [15] Soni LK, Solanki SS, Maheshwari RK. Solubilization of poorly water soluble drug using mixed solvency approach for aqueous injection. Br J Pharm Res. 2014;4:549. [16] Jenke D, Castner J, Egert T, et al. Extractables characterization for five materials of construction representative of packaging systems used for parenteral and ophthalmic drug products. PDA J Pharm Sci Technol. 2013;67:448-511. [17] Joshi M, Pathak S, Sharma S, Patravale V. Design and in vivo pharmacodynamic evaluation of nanostructured lipid carriers for parenteral delivery of artemether: Nanoject. Int. J. Pharm. 2008;364:119-26. [18] Amin K, Dannenfelser RM. In vitro hemolysis: guidance for the pharmaceutical scientist. J. Pharm. Sci. 2006;95:1173-6. [19] Deibler GE, Holmes MS, Campbell PL, Gans J. Use of triton X-100 as a hemolytic agent in the spectrophotometric measurement of blood O2 saturation. J. Appl. Physiol. 1959;14:133-6. [20] Saha CN, Bhattacharya S, Chetia D. Synthesis and Antimalarial Screening of Some New Isoquine Analogues. Int J ChemTech Res. 2009;1:322-8. [21] Wernsdorfer WH. In vitro tests for drug resistance in Plasmodium falciparum. The Indian J. Med. Res. 2012;135:456. [22] Choudhary P, Nagori B. Evaluation of In vitro Antimalarial Activity of Cassia Occidentalis. 2013. [23] Cilurzo F, Selmin F, Minghetti P, et al. Injectability evaluation: an open issue. AAPS PharmSciTech. 2011;12:604-9.


  • There are currently no refbacks.

Copyright (c) 2016 vaishali Tejas thakkar

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

               AR Journals

18K, Street 1st, Gaytri Vihar, Pinto Park, Gwalior, M.P. India

Copyright@arjournals.org (Design) 2009-2018


Follow @arjournals on Twitter